Free shipping on all orders over $ 500


Cat. No. M1819
A66 Structure
Size Price Availability Quantity
Free Sample (0.1-0.5 mg)  USD 0 In stock
2mg USD 57  USD57 In stock
5mg USD 95  USD95 In stock
10mg USD 167  USD167 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

A66 is a novel small molecule inhibitor of PI3K p110α with IC50 values of 32, 30 and 43 nM for p110α, p110α/E545K and p110α/H1047R. A66, showing the S-enantiomer to be a highly specific and selective p110α inhibitor. The responsive cell lines all harboured H1047R mutations in PIK3CA and have high levels of p110α and class-Ia PI3K activity. A66 is more than 100 fold less active against the other class-I PI 3-kinase isoforms and had not inhibitory activity against 200 protein kinases when tested at 10 micromolar. This makes it the most selective and specific p110α inhibitor available for research purposes.

Product Citations
Customer Product Validations & Biological Datas
Source OncoImmunology (2017). Figure 4. A66 (Abmole Bioscience, Houston, TX, USA)
Method oral gavage
Cell Lines BALB/C mice
Concentrations 100 mg/kg
Incubation Time 3 d
Results Under CD8+ T cell depletion, the anti-tumor efficacy of antineu antibody alone or in combination with GDC-0941 was slightly reduced, whereas that of antibody plus A66 was completely abolished
Source OncoImmunology (2017). Figure 3. A66 (Abmole Bioscience, Houston, TX, USA)
Method sulforhodamine B assay
Cell Lines TUBO-P2J cells
Concentrations 1 μM
Incubation Time 48 h
Results Furthermore, A66 in combination with the antibody prolonged survival
Source OncoImmunology (2017). Figure 1. A66 (Abmole Bioscience, Houston, TX, USA)
Method oral gavage
Cell Lines BALB/C mice
Concentrations 100 mg/kg
Incubation Time 3 d
Results In contrast to the pan-PI3K inhibitor, a PI3K p110α isoform-selective inhibitor (A66) alone had less effect on cell viability; however, anti-neu antibody combined with A66 acted synergistically to inhibit tumor cell survival
Protocol (for reference only)
Cell Experiment
Cell lines CD4+ T lymphocytes
Preparation method T lymphocyte isolation and activation
To obtain naive CD4+ T lymphocytes (CD4+CD62L+ T cells), spleens were passed through a 70 lm mesh. After centrifugation, red blood cells were lysed and the cells washed in culture medium (Click’s medium supplemented with 10% heat inactivated FCS). Then, naive CD4+ T cells were isolated using Miltenyi CD4+CD62L+ T cell isolation kit II for mouse cells (Ref. 130-093-227, Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturers’ instructions. The isolated cells were routinely >97% CD4+, >95% CD62L+. Cells (106) were cultured in 1 ml culture medium in 24- well culture plates (Costar) pre-coated with anti-CD3 antibody (YCD3-1, 5 lg ml 1). Where indicated, anti-CD28 (H57, 2.5 lg ml 1, eBioscience, San Diego, California), DMSO or inhibitors dissolved in DMSO (1 ll per culture) were added. At 24 h, the cultures were resuspended, centrifuged and the supernatants assayed for cytokine content.
Concentrations 0~10 μ M
Incubation time 24 h
Animal Experiment
Animal models mice bearing SK-OV-3, HCT-116 and U87MG xenograft models
Formulation 20% 2-hydroxypropyl-β-cyclodextrin (Sigma–Aldrich) in water
Dosages 10 ml/kg once daily (QD) or twice daily (BID) daily for 21 days or twice daily for 16 days (SK-OV-3), daily for 14 days (U87MG) and daily for 7 days (HCT-116)
Administration intraperitoneal injection
Chemical Information
Molecular Weight 393.53
Formula C17H23N5O2S2
CAS Number 1166227-08-2
Solubility (25°C) DMSO 50 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.


[1] Aragoneses-Fenoll L, et al. Biochem Pharmacol. ETP-46321, a dual p110α/δ class IA phosphoinositide 3-kinase inhibitor modulates T lymphocyte activation and collagen-induced arthritis.

[2] Smith GC, et al. Biochem J. Effects of acutely inhibiting PI3K isoforms and mTOR on regulation of glucose metabolism in vivo.

[3] Jamieson S, et al. Biochem J. A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types.

Related PI3K Products

PF-06843195 is a highly selective PI3Kα inhibitor with an IC50 of 18 nM in Rat1 fibroblasts.The Ki of PF-06843195 acting on PI3Kα and PI3Kδ is less than 0.018 nM and 0.28 nM, respectively.PF-06843195 has a significant inhibitory effect on PI3K/mTOR signaling pathway and had a long-lasting anti-tumor effect.


AZD8154 is a novel inhaled selective PI3Kγδ dual inhibitor targeting airway inflammatory diseases.


NVP-CLR457 is an orally administered, non-CNS-penetrating, pan-IA-like phosphoinositide 3-kinase (PI3K) inhibitor.NVP-CLR457 shows a significant dose-dependent PK / PD / efficacy relationship.NVP-CLR457 has antitumor activity.


ME-401 (PWT-143, P110δ-IN-1) is an oral, potent and selective inhibitor of Phosphatidylinositol 3-Kinase (PI3K) P110δ with IC50 of 0.6 nM in cellular assay.

3-Hydroxyanthranilic acid

3-Hydroxyanthranilic Acid (3-HAA, 3-HANA), a tryptophan metabolite, has an immunomodulatory effect that may result from inhibition of PI3K/Akt/mTOR and NF-κB activity, thereby decreasing the production of pro-inflammatory mediators.

Abmole Inhibitor Catalog

Keywords: A66 supplier, PI3K, inhibitors, activators

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.